In the BioHarmony Drug Report Database

"Preview" Icon

Glucagon

Baqsimi, Glucagon, Gvoke Hypopen, Gvoke Pfs, Ogluo (glucagon) is a protein pharmaceutical. Glucagon was first approved as Baqsimi on 1998-09-11. It is used to treat anaphylaxis, bradycardia, cardiogenic shock, hypoglycemia, and hypotension in the USA. It has been approved in Europe to treat diabetes mellitus. The pharmaceutical is active against glucagon receptor. In addition, it is known to target glucagon-like peptide 2 receptor and glucagon-like peptide 1 receptor. Glucagon’s patents are valid until 2039-09-23 (FDA).

 

Trade Name

 

Baqsimi, Ogluo
 

Common Name

 

glucagon
 

ChEMBL ID

 

CHEMBL266481
 

Indication

 

anaphylaxis, bradycardia, cardiogenic shock, diabetes mellitus, hypoglycemia, hypotension
 

Drug Class

 

Image (chem structure or protein)

Glucagon structure rendering